A startup from UCF’s School of Medicine applying exosome technology to regenerative medicine, drug delivery, non-invasive diagnostics, and medical device development. It aims to improve quality of life through innovative healthcare solutions for intractable diseases.
アカデミアにて研究開発された医療技術の展開を行うアメリカ・セントラルフロリダ大学医学部発ベンチャー(株)プロジェニサイトジャパン（本社：神戸市、代表取締役CEO：徐綾）は、この度COVID-19 診断の為のネ...
弊社はセントラルフロリダ大学医学部教授・同大学脳神経科学研究所所長の菅谷公伸博士が研 究開発を行った化合物及び最先端の医療技術（国際特許数・２８、申請中を含めると６０以上）の 市場展開を行ってゆき...
We are a company that researches, develops, manufactures, and sells glycoconjugates, such as glycoproteins and glycopeptides. The development of ADCs using glycan linkers is progressing in the pharmaceutical industry, and we are capable of conducting basic research and contract-based research on these products as well as supplying large quantities of API raw materials. We are also conducting new research and development using glycans, including in mRNA vaccines and other macromolecular LNPs. Our in-house glycosylated somatostatin is currently undergoing clinical trials (Phase 2a), and we plan to out-license the technology in the future.
EX-Fusion is Japan’s only private company dedicated to the commercialization of laser fusion reactors. This breakthrough technology has the potential to replace conventional energy sources and play a vital role in achieving carbon neutrality by 2050.
Development of cancer treatment equipment using optical electromagnetic waves
A startup using regenerative medicine technologies to produce and supply homogeneous, high-precision blood cells at scale. It streamlines infectious disease research and the evaluation of pharmaceuticals and functional materials for efficacy and safety, while also providing research cells, testing cells, and diagnostic kits.
